KYMOS buys the Italian company Pharmaprogress


KYMOS Pharma Services has bought the company Pharmaprogress, specialized in services of analysis and research by contract. Pharmaprogress has the GMP authorization granted by the Italian Medicines Agency and has a prominent position among the main pharmaceutical companies in the country.

“This acquisition allows us to position Italy as our main foreign market, followed closely by France, and at the same time our plans for advanced expansion five years ago to consolidate us as a relevant CRO for the European market,” says Joan Puig de Dou, CEO of KYMOS. Currently, its main markets are Italy, France, Switzerland, Germany and Portugal.

KYMOS Pharma Services, founded in 2001, is a Contracts Research Organization (CRO) that offers R & D and quality control services for the biotechnological, pharmaceutical, veterinary, phytosanitary, nutraceutical and cosmetic industries.
In 2015, it inaugurated its new laboratories in the Technological Park of Vallès.